All Gobivaz articles

News

First biosimilar version of J&J’s Simponi approved in Europe

2025-11-21T14:32:37Z

Authorisation of the biosimilar Gobivaz provides a substitute biologic medicine to Simponi for individuals with immune-mediated diseases.